These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27512662)

  • 41. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
    Park GT; Choi KC
    Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic virotherapy for human malignant mesothelioma: recent advances.
    Boisgerault N; Achard C; Delaunay T; Cellerin L; Tangy F; Grégoire M; Fonteneau JF
    Oncolytic Virother; 2015; 4():133-40. PubMed ID: 27512676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virus, Oncolytic Virus and Human Prostate Cancer.
    Liu GB; Zhao L; Zhang L; Zhao KN
    Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.
    Chaurasiya S; Fong Y; Warner SG
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
    Zheng M; Huang J; Tong A; Yang H
    Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
    Rosewell Shaw A; Suzuki M
    Front Immunol; 2018; 9():2103. PubMed ID: 30298067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].
    Matveeva OV; Kochneva GV; Zainutdinov SS; Ilyinskaya GV; Chumakov PM
    Mol Biol (Mosk); 2018; 52(3):360-379. PubMed ID: 29989571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncolytic virotherapy for urological cancers.
    Delwar Z; Zhang K; Rennie PS; Jia W
    Nat Rev Urol; 2016 Jun; 13(6):334-52. PubMed ID: 27215429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promising oncolytic agents for metastatic breast cancer treatment.
    Cody JJ; Hurst DR
    Oncolytic Virother; 2015; 4():63-73. PubMed ID: 27512671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
    Cassidy T; Craig M
    PLoS Comput Biol; 2019 Nov; 15(11):e1007495. PubMed ID: 31774808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The advent of oncolytic virotherapy in oncology: The Rigvir® story.
    Alberts P; Tilgase A; Rasa A; Bandere K; Venskus D
    Eur J Pharmacol; 2018 Oct; 837():117-126. PubMed ID: 30179611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncolytic virus therapy for cancer: the first wave of translational clinical trials.
    Patel MR; Kratzke RA
    Transl Res; 2013 Apr; 161(4):355-64. PubMed ID: 23313629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Current state of oncolytic virotherapy in Japan].
    Nakamori M; Yamaue H
    Gan To Kagaku Ryoho; 2013 May; 40(5):553-8. PubMed ID: 23863576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
    Koks CA; De Vleeschouwer S; Graf N; Van Gool SW
    J Cancer; 2015; 6(3):203-17. PubMed ID: 25663937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
    Munguia A; Ota T; Miest T; Russell SJ
    Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.